ArticleFrontiers in psychology2021
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
Article in Frontiers in psychology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Esketamine With or Without Psychedelic Preparation and Integration for Treatment-Resistant Depression: A Randomized Controlled Trial
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of psilocybin on cognitive function: A systematic review.Psychiatry and clinical neurosciences · 2024Pooled it
- Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- A contemporary exploration of motivations and practices of psychedelic use among emerging adult cannabis users in the United States: A qualitative analysis.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2026Article
- Review
- Competencies and Ethical Governance for Psychedelic‑Assisted Therapies: A Practice‑Embedded Quality‑Improvement Framework.Journal of evaluation in clinical practice · 2026Article
- Not a Standalone Treatment: Considerations for Psychedelic-Assisted Therapy.Brain and behavior · 2026Review
- A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program.Journal of palliative medicine · 2026Article
- Designing evaluation infrastructure for psychedelic harm reduction at events: a methodological framework with formative mixed-methods field application.Frontiers in public health · 2026Article
- Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.Current topics in behavioral neurosciences · 2026Review
- Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.Current topics in behavioral neurosciences · 2026Review
- Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework.Frontiers in psychiatry · 2026Article
- Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service.Frontiers in public health · 2026Article
- Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis.Harm reduction journal · 2025Article
- Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.Harm reduction journal · 2025Article
- Harm reduction practises for users of psychedelic drugs: a scoping review.Harm reduction journal · 2025Article
- The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry.Journal of personalized medicine · 2025Review
- Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms.Psychiatry and clinical psychopharmacology · 2025Article
- Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.Brain and behavior · 2025Article
- The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.Journal of psychopharmacology (Oxford, England) · 2025Article
- Participants' Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis.Psychedelic medicine (New Rochelle, N.Y.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and transdiagnostic clinical approach to working with patients who are using or considering using psychedelics in any context. The ongoing discussion of psychedelics in academic research and mainstream media, coupled with recent law enforcement deprioritization of psychedelics and compassionate use approvals for psychedelic-assisted therapy, make this model exceedingly timely. Given the prevalence of psychedelic use, the therapeutic potential of psychedelics, and the unique cultural and historical context in which psychedelics are placed, it is important that mental health providers have an understanding of the unique motivations, experiences, and needs of people who use them. PHRI incorporates elements of harm reduction psychotherapy and psychedelic-assisted psychotherapy, and can be applied in both brief and ongoing psychotherapy interactions. PHRI represents a shift away from assessment limited to untoward outcomes of psychedelic use and abstinence-based addiction treatment paradigms and toward a stance of compassionate, destigmatizing acceptance of patients' choices. Considerations for assessment, preparation, and working with difficult experiences are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.